European FMD Research Funding - Food and Agriculture … · · 2013-05-17European FMD Research...
Transcript of European FMD Research Funding - Food and Agriculture … · · 2013-05-17European FMD Research...
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
European FMD Research Funding
David Paton
Rome April 2013
FP7
Epi-SEQ DISCONVAC
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
DISCONVAC: Development, enhancement and complementation of animal-sparing, foot-and-mouth disease vaccine-based control strategies for free and endemic regions
1st April 2009 – 31st June 2013
14 partners including vaccine producers from Europe and India and Research
Institutes from China and Argentina
Objectives
(i) improve the quality of existing FMD vaccines and diagnostics,
(ii) refine and replace in vivo vaccine quality tests,
(iii) develop new generation FMD vaccines and diagnostics by cutting edge technology,
(iv) increase/enhance our knowledge on FMDV spread and transmission following the
use of high-potency monovalent or multivalent vaccines in free and endemic settings.
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
DISCONVAC:
Publications (1)
Interplay of FMDV, antibodies and plasmacytoid dendritic cells: virus opsonization
under nonneutralizing conditions results in enhanced interferon-alpha responses
Interferon-gamma induced by in vitro re-stimulation of CD4-+ T cells correlates with in
vivo FMD vaccine induced protection of cattle against disease and persistent infection.
Characteristics of serology based vaccine potency models for FMDV
Reducing animal experimentation in FMD vaccine potency tests.
Intranasal Delivery of Cationic PLGA Nano/Microparticles-Loaded FMDV DNA Vaccine
Encoding IL-6 Elicited Protective Immunity against FMDV Challenge.
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
Avidity and subtyping of specific antibodies applied to the indirect assessment of
heterologous protection against FMDV in cattle.
Evaluation of cross-protection between O-Manisa and O-Campos in cattle vaccinated
with different payloads of O-Manisa vaccine.
Development of a FMD infection model in severe combined immunodeficient mice for
the preliminary evaluation of antiviral drugs.
Validation of a recombinant integrinavb6/monoclonal antibody based antigen ELISA
for the diagnosis of FMD.
DISCONVAC:
Publications (2)
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
1st May 2012 – for 36 months
Internal funding through EMIDA selection system; 6 partners (all European Public
Institutes)
Focus on key diseases caused by RNA viruses (FMDV, AIV, NDV, CSFV) and DNA
viruses (ASFV and exotic poxviruses).
Will exploit advances in next-generation sequencing (NGS) techniques that offer
unprecedented increases in the scale of sequence data generated from a sample.
1. How to sequence large collections of viruses to parameterize improved models
that describe viral transmission and outbreak epidemiology.
2. How to conduct deep re-sequencing of viral sequences within single samples to
define the evolutionary dynamics of viruses.
Epi-SEQ
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
Rapid Field Diagnostic and Screening in Veterinary Medicine
Development of penside tests that can be used to support local decision-making
by animal health practitioners.
Also test formats for use in non-specialised frontline laboratories.
Multiple pathogens
12 partners from 8 different countries: five companies (all SME) and seven
public research organizations.
1st January 2012 – for 36 months
Collaborative Project (Small or medium-scale focused research project targeted
to SMEs)
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
Follow-on to EMIDA and also utilises national funding
IRAFTOVAC - Anihwa FMD proposal (€ 2.2m), currently under review (decision in May,
for Sep start). 71 other proposals (non-FMD)
7 European partners including one vaccine producer
Aims to:
1. Generate vaccines inducing long term immunity
2. Determine early biomarkers and mechanisms linked to long term immunity
3. Develop novel viral vectored vaccines and VLPs for increasing adaptive and
local immune responses
4. Understand the molecular mechanism of FMDV persistence
5. Develop improved diagnostics to monitor FMDV status
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
EU FMD Funding from mid-2013
• No FMD-specific funding
• No plans for FMD-specific calls?
• Ongoing funding: – Nationally funded
– Part of multi-pathogen projects
• EPIZONE funding also finished
• Loss of critical mass
• Unfulfilled research requirements
• Need for advocacy
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
National FMD funding • Solicited information on FMD funding 2010-2014, from 6
countries – UK, Germany, France, Italy, Denmark, The Netherlands
• Quite diverse levels of funding for FMD activities – Excluding UK, €0.4m - €1.1m and 1-12 FTE staff
• National funding stagnant or slightly decreased in most cases – Most funds available for Ref Lab functions
– Only 2 countries provide significant amounts of FMD research funding
• Heavy reliance on EC funds for research activities – Reduced funding associated with end of DISCONVAC project
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
Observations on FMD funding
• Increases in funding after 2001 now draining away
• Lack of research funding is paradoxical when pressing for global FMD control
• Need to create a European fund for FMD research
• Need more cooperation between MS to provide shared functions
• Problem of where next generation of FMD experts will come from
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
Global FMD Research Alliance (GFRA)
• Expanded membership
• Themed Research meetings
FMD Cross-protection, Vaccine-matching and Vaccine Banks:
Challenges and Opportunities
Buenos Aires, Argentina
June 14-16, 2011
Surveillance, Epidemiology, Vaccination and Control of FMD
Hosted by the ARC-OVI in the Kruger National Park, South Africa
April 17-19, 2012
• Success has led to development of similar networks for PPR and ASF
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
Isothermal nucleic acid amplification plus LFD read-out
Can detect epithelial and air
samples without RNA
extraction
Similar sensitivity to rRT-PCR
Basis for simple but highly
sensitive field assay
Sensitive and simple penside tests
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
FMDV Capsid vaccines – safe and stable
Porta et al. (2013) PLoS Pathogens
Stabilised capsids treated 2h at 56ºC (or for 30min at pH5) are intact after sucrose density gradient analysis
“The science behind the new foot-and-mouth disease vaccine
The creation of a new synthetic vaccine for foot-and-mouth disease is a stranger
and more impressive tale than reported in the media”
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
Surveillance and research needs
“Free” countries • Early warning
• Safe trade
• Rapid detection
• Rapid onset vaccines/antivirals
• Safe and storable vaccines
• DIVA vaccines/tests
• Understand epidemiology
• Decision support tools
“Endemic” countries • Monitoring in complex
epidemiological situations
• Simple diagnostics
• Understand epidemiology
• Cheap, stable vaccines that give long-term and broad protection
• Technology transfer
40th General Session of the EuFMD • 22-24 April 2013, Rome (Italy)
Acknowledgements
Thanks to those who provided funding information